Published in
American Society of Hematology, Blood, 25(126), p. 2713-2719, 2015
DOI: 10.1182/blood-2015-06-650242
Links
- ORCID
- ORCID
- ORCID
- ORCID
- ORCID
- American Society of Hematology | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Journal article published in 2015 by
Marie-Lorraine Chretien,
Chretien Ml,
Jill Corre 
,
Valerie Lauwers-Cances,
Florence Magrangeas ,
Alice Cleynen,
Edwige Yon,
Cyrille Hulin,
Xavier Leleu,
Frederique Orsini-Piocelle,
Jean-Sebastien Blade,
Claudine Sohn,
Lionel Karlin,
Benjamin Hebraud,
Xavier Delbrel
and other authors.
,
Valerie Lauwers-Cances,
Florence Magrangeas ,
Alice Cleynen,
Edwige Yon,
Cyrille Hulin,
Xavier Leleu,
Frederique Orsini-Piocelle,
Jean-Sebastien Blade,
Claudine Sohn,
Lionel Karlin,
Benjamin Hebraud,
Xavier Delbrel
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points In myeloma patients, trisomy 3 improved time to progression and trisomies 3 and/or 5 improved overall survival. In contrast, trisomy 21 significantly worsened overall survival.